CARNA BIOSCIENCES

News Release

November 6, 2024
Carna Biosciences, Inc.

Carna announces acceptance of two posters on docirbrutinib (AS-1763) for presentation at ASH Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announces that two posters on docirbrutinib (AS-1763) will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition.

Docirbrutinib, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including existing covalent/non-covalent BTK inhibitors. Dr. Natalia Timofeeva, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, will present preclinical findings of docirbrutinib using blood samples obtained from CLL patients treated with docirbrutinib. Also, preliminary data from ongoing Phase 1b study will be presented by Prof. Nitin Jain, MD, Department of Leukemia, MD Anderson and all the other principal investigators at the participating clinical sites. The ASH Annual Meeting and Exposition will take place December 7-10, 2024, in San Diego, California.

Presentation Details

Publication Number: 1850

Poster title:	Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers
Session:	641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I
Session date:	December 7, 2024
Presenter:	Natalia Timofeeva, MD[1], Breana Herrera[1], Shady I. Tantawy, MD[1], Hitomi Fujiwara, PhD[2], Mariko Hatakeyama[2], Lizbeth Loza[1], Tokiko Asami[2], Hiroshi Ohmoto[2], Kyoko Miyamoto, MD, PhD[3], Yu Nishioka[2], Akinori Arimura, PhD[3], Masaaki Sawa, PhD[2], Nitin Jain, MD[1] and Varsha Gandhi, PhD[1]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX; [2]Carna Biosciences, Inc., Kobe, Japan; [3]CarnaBio USA, Inc., South San Francisco, CA

The abstract is now available at:

URL: https://ash.confex.com/ash/2024/webprogram/Paper210788.html

Publication Number: 1866

Poster title:	Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
Session:	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
Session date:	December 7, 2024
Presenter:	Nitin Jain, MD[1], Catherine C. Coombs, MD[2], James D'Olimpio, MD[3], Nirav N. Shah, MD[4], Jacqueline C. Barrientos, MD[5], Seung Tae Lee, MD, PhD[6], Andrew Gillis-Smith, MD[7], Shuo Ma, MD, PhD[8], Shirou Kirita[9], Masaaki Sawa, PhD[9], Kyoko Miyamoto, MD, PhD[10], Akinori Arimura, PhD[10], William G. Wierda, MD, PhD[1], Varsha Gandhi, PhD[1] and Javier Pinilla-Ibarz, MD, PhD[11]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX; [2]University of California Irvine, Irvine, CA; [3]Clinical Research Alliance, Westbury, NY; [4]Medical College of Wisconsin, Milwaukee, WI; [5]Mount Sinai Medical Center, Miami Beach, FL; [6]University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, MD; [7]University of Massachusetts Memorial Medical Center, Worcester, MA; [8]Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; [9]Carna Biosciences, Inc., Kobe, Japan; [10]CarnaBio USA, Inc., South San Francisco, CA; [11]H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

The abstract is now available at:

URL: https://ash.confex.com/ash/2024/webprogram/Paper208549.html

About docirbrutinib (AS-1763)

Docirbrutinib is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S - 2 -mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. Docirbrutinib potently inhibited both wild type and those mutant BTKs, strongly suggesting that docirbrutinib will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of docirbrutinib as a next-generation BTK inhibitor.

The Phase 1b study of docirbrutinib is being conducted in the U.S. and dosing in the dose expansion part was initiated in October 2024. Preliminary data from the study which was presented at the European Hematology Association (EHA) 2024 Hybrid Congress in June 2024 by Prof. Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, who leads the study showed a favorable safety and PK profile as well as promising efficacy in patients with CLL who have been heavily pretreated with systemic therapies including covalent BTK inhibitors and BCL2 inhibitor.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/